On Wednesday, SolarWinds Inc (NYSE:SWI)’s shares inclined 0.23% to $39.12.
SolarWinds (NYSE: SWI), a leading provider of powerful and affordable hybrid IT infrastructure administration software, declared its participation at VMworld US 2015, August 30-September 3, 2015, in San Francisco. At the event, SolarWinds will exhibit its latest solutions for managing virtualized and hybrid IT environments, counting new capabilities to assist patch virtual systems. In addition, SolarWinds will host its second annual Experts & Espresso event, a series of free morning learning sessions, and Head Geek Thomas LaRock will present alongside VMware and Heraflux Technologies at two database virtualization breakout sessions.
SolarWinds, Inc., together with its auxiliaries, designs, develops, markets, sells, and supports enterprise-class information technology (IT) and infrastructure administration software to IT and DevOps professionals in various organizations worldwide. The company offers enterprise-class network administration products and tools that allow network administrators and other IT professionals to monitor and manage the performance and configuration of their network infrastructure, in addition to to collect and analyze the log data for IT operations, security, and compliance administration.
CME Group Inc (NASDAQ:CME)’s shares gained 1.58% to $92.56.
CME Group, the world’s leading and most diverse derivatives marketplace, recently declared that July 2015 volume averaged 12.8 million contracts per day, up 5 percent from July 2014. Total volume was more than 282 million contracts, of which 87 percent was traded electronically. Options volume in July averaged 2.9 million contracts per day, up 22 percent as compared to July 2014, with electronic options growing 36 percent over the same period.
CME Group interest rate volume averaged 5.9 million contracts per day in July 2015, down 5 percent contrast with July 2014. Treasury average daily volume rose 3 percent, with treasury futures volume of 2.2 million contracts per day, down 2 percent from the same period a year ago. Treasury options volume grew 27 percent to more than 634,000 contracts per day and comprised of record weekly treasury options average daily volume of 147,707. Eurodollar futures volume averaged 2.1 million contracts per day, down 20 percent contrast with July 2014. Eurodollar options volume averaged 927,000 contracts per day, up 14 percent, driven by 62 percent growth in Eurodollar options traded on the CME Globex platform. In July, 21 percent of the Eurodollar options volume traded electronically.
CME Group Inc., through its auxiliaries, operates contract markets for the trading of futures and options on futures contracts worldwide. It offers a range of products for trading and/or clearing across various asset classes, based on interest rates, equity indexes, foreign exchange, energy, agricultural commodities, and metals.
At the end of Wednesday’s trade, Fluor Corporation (NEW) (NYSE:FLR)‘s shares surged 0.64% to $44.35.
Fluor Corporation (NEW) (FLR) declared that the U.S.-China Business Council (USCBC) has elected Fluor’s Chief Operating Officer, Peter Oosterveer, to its board. As a USCBC board member, Oosterveer will work to advance the commercial relationship between the two countries to support trade and investment opportunities.
Fluor Corporation, through its auxiliaries, provides engineering, procurement, construction, fabrication and modularization, commissioning and maintenance, and project administration services worldwide. The company operates in five segments: Oil & Gas, Industrial & Infrastructure, Government, Global Services, and Power. The Oil & Gas segment offers a range of design, engineering, procurement, construction, and project administration services to upstream oil and gas production, liquefied natural gas, downstream refining, offshore production, pipeline, chemicals, and petrochemicals industries. It also provides consulting services comprising feasibility studies, process assessment, and project finance structuring and studies.
Medivation Inc (NASDAQ:MDVN), ended its Wednesday’s trading session with 4.65% gain, and closed at $89.54.
Medivation, Inc. ( MDVN) stated its financial results for the second quarter ended June 30, 2015. U.S. net sales of XTANDI® (enzalutamide) capsules, as stated by Astellas Pharma Inc., were $298.4 million for the quarter (+108% vs. preceding year). Second quarter U.S. net sales raised by 33% contrast with first quarter 2015 net sales of $224.0 million. We estimate second quarter 2015 unit demand raised by a low- to mid-teens percentage rate, contrast with unit demand in the first quarter 2015. In addition, based on information offered by Astellas, a lower gross-to-net discount rate was applied to second quarter gross sales (contrast with the first quarter rate), and a $2.8 million favorable adjustment was recorded in the second quarter by Astellas with respect to gross-to-net discount related to previous period gross sales.
Medivation, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies to treat serious diseases in the United States. It offers XTANDI for the treatment of post-chemotherapy metastatic castration-resistant prostate cancer (mCRPC) patients.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
